- SS Innovations International rings the opening bell at Nasdaq, marking a proud milestone in India’s journey toward global leadership in advanced medical technology.
- The SSI Mantra Surgical Robotic System is now approved for marketing not only in India but also in Nepal, Ecuador, Guatemala, the Philippines, Indonesia, and Ukraine.
- SS Innovations International’s revenue surged to $20.6 million in 2024 — a 5x increase over 2023 — with gross margin improving to 40.9%
- SS Innovations reinforces India’s position as a hub for technological innovation in healthcare using SSI Mantra – Made in India, for the World.
New Delhi: In a defining leap for Indian medical technology on the global stage, SS Innovations International, the creators of the indigenous SSI Mantra surgical robotic system — rang the opening bell today at the Nasdaq MarketSite in New York City. The company’s shares are listed under the ticker symbol ‘SSII’.
The ceremony was led by Dr. Sudhir Srivastava, Founder, Chairman, and CEO of SS Innovations International, joined by members of the company’s management team, Board of Directors, key advisors, and special guests. This milestone marks a proud moment for India, underscoring the nation’s growing leadership in advanced medical technologies and heralding a new era of innovation and international recognition for Indian-origin healthcare solutions.
SS Innovations International has made remarkable progress with its clinically validated and patented SSI Mantra Surgical Robotic System, which has been installed in 80 hospitals across 75 locations in India. The company has also expanded its presence internationally to countries including Nepal, Ecuador, Guatemala, the Philippines, Indonesia, Sri Lanka, and Ukraine. With over 4,000 successful robotic surgeries completed across more than 100 surgical procedures, the SSI Mantra is transforming access to advanced robotic surgery by offering a cost-effective solution to a broader patient population. With plans to expand into Europe and the United States, SS Innovations is positioning itself as a global leader in medical robotics, further solidifying India’s pivotal role in shaping the future of healthcare technology worldwide.
Expressing immense happiness and gratitude on the occasion of SS Innovations International ringing the opening bell at NASDAQ, Dr. Sudhir Srivastava, Founder, Chairman, and CEO, said, “Today’s bell-ringing ceremony marks a proud moment for all of us at SS Innovations International, commemorating our successful uplisting to Nasdaq in April 2025. This milestone reflects the relentless dedication of our team in developing the SSI Mantra, an advanced, cost-effective and world-class surgical robotic system designed and built in India. We are also celebrating the successful completion of over 4,000 robotic procedures across more than 100 types of surgeries, with zero complications, injuries or mortalities, which is a testament to the system’s precision and safety. The SSI Mantra is now gaining strong traction among surgeons not just across India but also in six other countries, and we are actively working to expand into key global markets, including the European Union and the United States. Our mission remains clear: to make cutting-edge robotic surgery accessible and affordable for patients worldwide, with India at the forefront.”
SS Innovations International reported impressive financial growth for the year ending December 31, 2024, with revenues reaching $20.6 million — a 3.5-fold increase from the previous year’s revenue of $5.9 million. Gross margins also showed significant improvement, rising to 40.9% from 12.3% in 2023, highlighting the company’s robust financial performance and expanding market presence.
The ringing of the opening bell at Nasdaq by SS Innovations International symbolizes a landmark moment in India’s healthcare journey. This achievement underscores SSI’s commitment to transforming surgical care through innovative technology and a compassionate mission to broaden access to affordable, state-of-the-art robotic surgery worldwide.
About SS Innovations:
SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. The Company’s product range includes its proprietary “SSI Mantra” surgical robotic system, and “SSI Mudra” its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SS Innovations’ business operations are headquartered in India and the Company plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally.
About the SSI Mantra:
The SSI Mantra Surgical Robotic System, by SS Innovations, is a modular multi-arm system with many advanced technology features. It allows for the use of 3-5 robotic arms, has an open- faced ergonomic Surgeon Command Centre, 32-inch large 3D 4K monitor, a 23-inch 2D Touch panel monitor for all patient related information display, a virtual real-time image of the robotic Patient Side Arm Carts, and the ability for superimposition of 3D models of diagnostic imaging. The Vision Cart gives the table-side team the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The modular robotic arms give flexibility in positioning and the number of arms to be used. This allows for collision-free conduct of surgical operations. There are over 40 different types of robotic endo-surgical instruments that can be used for different specialties including cardiac surgery. The learning curve for surgeons is shorter due to the SSI Mantra’s ergonomic design and user-friendly features.
The SSI Mantra has been clinically validated in India in more than 90 different types of surgical procedures. SS Innovations has commenced the regulatory approval process in the United States and the European Union and anticipates receiving FDA approval to market and CE Mark approval in the second half of 2025.
Discussion about this post